Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol for EPO consumption in calcitriol-resistant CKD
NCT01506947Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2012
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
01
Overview
A Phase 4 trial of paricalcitol in secondary hyperparathyroidism (SHPT), sponsored by AbbVie Inc.. Started May 2012; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01506947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01506947.